Can a new blood test catch congenital toxoplasmosis earlier?
NCT ID NCT03385499
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial evaluates a new blood test (ELISPOT) that looks for immune cells in a newborn's cord blood that produce antibodies against the Toxoplasma parasite. The goal is to see if this test can diagnose congenital toxoplasmosis—an infection passed from mother to baby during pregnancy—more accurately and earlier than current methods. The study includes pregnant women with recent infection, past infection, or no infection, and compares test results across these groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ELISPOT blood test to detect newborn immune cells producing Toxoplasma-specific antibodies
- What this could lead to
- If successful, this could lead to a faster, more reliable diagnostic test for congenital toxoplasmosis, enabling earlier treatment and better outcomes for infected newborns.
- What could go wrong
- This is a small, early-stage diagnostic study, so the test may not prove accurate enough or practical for routine use. It is not a treatment trial and offers no direct benefit to participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL TOXOPLASMOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Bichat
Paris, France
-
Hopital Cochin
Paris, France
-
Hopital Louis Mourier
Colombes, 92700, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.